Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with

umbralisib
btk inhibitor
diffuse large b-cell lymphoma
mantle cell lymphoma
b-cell lymphoma
  • 12 views
  • 22 Sep, 2021
  • 204 locations
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects

lymphoid leukemia
monoclonal protein
chronic lymphocytic leukemia
venetoclax
monoclonal antibodies
  • 21 views
  • 23 Sep, 2021
  • 43 locations
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

lymphoid leukemia
platelet count
btk inhibitor
monoclonal protein
monoclonal antibodies
  • 0 views
  • 29 Mar, 2021
  • 1 location
  • 0 views
  • 28 Feb, 2021
  • 1 location
Acalabrutinib Umbralisib and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

This phase II trial studies the effects of acalabrutinib, umbralisib, and ublituximab in treating previously untreated mantle cell lymphoma. Acalabrutinib and umbralisib may stop the growth of

ejection fraction
mantle cell lymphoma
cytopenia
monoclonal antibodies
cyclin d1
  • 0 views
  • 21 Aug, 2021
  • 1 location
TGR-1202 (Umbralisib) in Treatment Na ve Patients With Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)

lymphoid leukemia
lymphadenopathy
anemia
fatigue
constitutional symptoms
  • 1 views
  • 03 Jul, 2021
  • 1 location
Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Na ve Follicular Lymphoma

This is a phase 2, open label study to assess umbralisib in combination with ublituximab in subjects with treatment nave Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).

umbralisib
monoclonal protein
chronic lymphocytic leukemia
follicular lymphoma
measurable disease
  • 52 views
  • 22 Sep, 2021
  • 3 locations
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.

experimental drug
umbralisib
cytopenia
cancer
gilbert's syndrome
  • 1 views
  • 25 Jan, 2021
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

This phase II trial studies how well umbralisib and pembrolizumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment

cancer
platelet count
refractory classical hodgkin lymphoma
classical hodgkin lymphoma
avid
  • 0 views
  • 04 Sep, 2021
  • 1 location
AU2 In Relapsed and Untreated CLL

This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL). The names of

  • 0 views
  • 16 May, 2021
  • 3 locations